Rigorous research has been conducted with the Woman’s Condom (branded as O’LavieTM in China) in several countries to evaluate and validate the product’s
safety, performance, and acceptability. These studies have found that the
Woman’s Condom is safe, acceptable, and easy to use, and that it performs well when compared to other female condom products.1-5
Additional clinical studies are in process, including a contraceptive effectiveness study taking place in the United States.
For optimal effectiveness, the Woman’s Condom must be used consistently and correctly each time a couple has sex.
Completed clinical studies of the Woman’s Condom
1. Coffey PS, Kilbourne-Brook M, Austin G, Seamans Y, Cohen J. Short-term acceptability of the PATH Woman’s Condom at three sites. Contraception. 2006;73(6):588–593.
2. Schwartz JL, Barnhart K, Creinin MD, et al. Comparative crossover study of the PATH Woman’s Condom and the FC Female Condom®. Contraception. 2008;78(6):465–473.
3. Joanis C, Beksinska M, Hart C, et al. Three new female condoms: which do South African women prefer? Contraception. 2011;83(3):248–254.
4. Zirong H, Junqing W, Coffey PS, et al. Performance of the Woman’s Condom among couples in Shanghai, China. The European Journal of Contraception and Reproductive Health Care. 2012;17(3):212–218.